The global animal vaccines market size is expected to reach USD 16.27 billion by 2028 according to a new study by Polaris Market Research. The report “Animal Vaccines Market Share, Size, Trends, Industry Analysis Report, By Product (Attenuated Live Vaccines, Inactivated, Subunit, DNA, Recombinant); By Animal Type; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The increasing cases of zoonotic diseases and the rising number of infectious diseases in different types of meat that are slowing the growth of the industry will be the main factors responsible for the development of the global market. The emergence of modern recombinant injections and the investment by governments for mass immunization programs are anticipated to fuel the market growth further.
Zoonotic diseases have been shared across the globe in the past few decades, and more than half of the emerging infectious diseases worldwide are originated from pets. Many diseases have been transmitted from pets to humans, such as Swine flu. Hence, it is necessary to vaccinate food and pets to prevent any such disease from spreading in the coming years.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/animal-vaccines-market/request-for-sample
The introduction of new and innovative technologies such as recombinant serums will develop innovative products in the coming years. These inoculations can overcome the limitations of conventional medicines and hence will be widely adopted. For instance, in April 2021, ICAR-CIBA launched a recombinant vaccine CIBA-Nodavac-R against nervous necrosis virus (NNV), which affects marine, brackish water, and freshwater fish that results in 100 % mortality in early juvenile and larval stages.
Numerous developments are taking place in the market with the launch of many medications and acquisitions, funding, and collaborations. Zoetis launched the porcine vaccine CircoMax Myco in May 2021, the only vaccine for the protection against Mycoplasma hyopneumoniae and PCV2. Applied LifeSciences & Systems (ALSS) raised USD 7 million in recent funding in May 2021 to automate poultry vaccination systems.
Market participants include Zoetis, Biogénesis Bagó, Boehringer Ingelheim International GmbH, Ceva, Elanco, Indian Immunologicals Ltd., Intas Pharmaceuticals Ltd., Merck & Co., Inc., Neogen Corporation, Ourofino Saúde Animal, Phibro Animal Health Corporation, and Virbac are some of the key players operating in the global market.
Polaris Market research has segmented the animal vaccines market report on the basis of product, animal type, and region
Animal Vaccines, Product Outlook (Revenue – USD Million, 2016 – 2028)
- Attenuated live vaccines
- Inactivated vaccines
- Subunit vaccines
- DNA vaccines
- Recombinant vaccines
Animal Vaccines, Animal Type Outlook (Revenue – USD Million, 2016 – 2028)
- Infectious bronchitis
- Avian influenza
- Marek’s disease
- Newcastle disease
- Foot & Mouth Disease (FMD)
- Lumpy skin
- Kennel cough
- Canine herpes
- Lyme disease
- Swine influenza
- Classical Swine Fever (CSF)
- Porcine Parvovirus (PPV)
- Porcine Circovirus Type 2 (PCV2)
- Actinobacillus Pleuropneumoniae
- Foot & mouth disease
- PEDV (coronavirus)
Animal Vaccines, Regional Outlook (Revenue – USD Million, 2016 – 2028)
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa